ENRIGHT PATRICK G — SEC insider filings
SEC reporting owner CIK 1253886. 52 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers the 50 most recent of 52 filings on record, filed 2020-09-23 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 20 legs across 15 filings — 7,847,723 shares, $93,652,242 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 7 filings — 676,972 shares, $78,697,290 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 95.
- Largest priced transaction: sale of 250,000 shares @ $150.38 ($37,595,000) in Veradermics, Inc, filed 2026-11-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Veradermics, Inc (MANE) | Director | 2 | 2 legs · 1,075,000 sh · $18,275,000 | 2 legs · 500,000 sh · $75,190,000 | 7 |
| Vera Therapeutics, Inc. (VERA) | Director | 11 | 8 legs · 3,212,590 sh · $32,527,276 | — | 8 |
| Zenas BioPharma, Inc. (ZBIO) | Director | 4 | 3 legs · 557,255 sh · $9,730,026 | — | 9 |
| BioAge Labs, Inc. (BIOA) | Director | 3 | 1 leg · 400,000 sh · $7,200,000 | — | 5 |
| Lexeo Therapeutics, Inc. (LXEO) | 10% owner | 1 | 1 leg · 454,545 sh · $4,999,995 | — | 4 |
| Inozyme Pharma, Inc. (INZY) | 10% owner | 1 | 1 leg · 1,355,000 sh · $4,999,950 | — | — |
| Sierra Oncology, Inc. (SRRA) | 10% owner | 3 | 1 leg · 175,000 sh · $4,725,000 | — | 10 |
| Eargo, Inc. (EAR) | 10% owner | 2 | 1 leg · 233,333 sh · $4,199,994 | — | 4 |
| Talaris Therapeutics, Inc. (TALS) | 10% owner | 1 | 1 leg · 235,000 sh · $3,995,000 | — | 4 |
| RAPID MICRO BIOSYSTEMS, INC. (RPID) | 10% owner | 3 | 1 leg · 150,000 sh · $3,000,000 | 5 legs · 157,739 sh · $663,949 | 11 |
+4 more issuers among the filings shown — every filing appears in the table below.
Insider filings — ENRIGHT PATRICK G
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Veradermics, Inc (MANE) | Sale (S): 250,000 @ $150.38 · Sale (S): 250,000 @ $150.38 | EDGAR |
| 2026-09-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Tax withholding (F): 14 @ $244.64 · Tax withholding (F): 1,692 @ $241.39 | EDGAR |
| 2026-08-07 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 1,605 @ $0 | EDGAR |
| 2026-06-17 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | RAPID MICRO BIOSYSTEMS, INC. (RPID) jointly with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Tammenoms Bakker Juliet | Sale (S): 49,000 @ $3.88 | EDGAR |
| 2026-02-05 | 4 | Veradermics, Inc (MANE) | Conversion (C): 1,236,631 · Conversion (C): 1,171,121 · Conversion (C): 1,171,121 · Purchase (P): 192,647 @ $17 · Purchase (P): 882,353 @ $17 · Conversion (C): 1,236,631 (derivative) · +3 more | EDGAR |
| 2026-02-03 | 4 | RAPID MICRO BIOSYSTEMS, INC. (RPID) jointly with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, Tammenoms Bakker Juliet | Option exercise/expiry (X): 629,032 @ $0.05 · Sale (S): 7,739 @ $4.06 · Sale (S): 46,000 @ $4.54 · Sale (S): 27,500 @ $4.25 · Sale (S): 27,500 @ $4.24 · Option exercise/expiry (X): 500,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-08 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Other (J): 5,000 @ $0 | EDGAR |
| 2025-12-15 | 4 | Vera Therapeutics, Inc. (VERA) | Purchase (P): 5,882 @ $42.50 | EDGAR |
| 2025-10-14 | 4 | Zenas BioPharma, Inc. (ZBIO) | Purchase (P): 105,265 @ $19 · Purchase (P): 11,990 @ $20.85 | EDGAR |
| 2025-08-11 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,507 @ $0 · Tax withholding (F): 1,805 @ $111.25 | EDGAR |
| 2025-06-25 | 4 | Vera Therapeutics, Inc. (VERA) | Purchase (P): 69,798 @ $20.87 · Purchase (P): 139,595 @ $20.87 · Purchase (P): 13,536 @ $22.35 · Purchase (P): 27,071 @ $22.35 | EDGAR |
| 2025-06-12 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2024-09-27 | 4 | BioAge Labs, Inc. (BIOA) | Conversion (C): 1,310,589 · Purchase (P): 400,000 @ $18 · Grant/award (A): 15,000 (derivative) @ $0 · Conversion (C): 5,848,637 (derivative) | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) | Conversion (C): 723,812 · Conversion (C): 1,003,592 · Conversion (C): 334,530 · Purchase (P): 440,000 @ $17 · Conversion (C): 6,284,933 (derivative) · Conversion (C): 8,714,293 (derivative) · +2 more | EDGAR |
| 2024-08-06 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,731 @ $0 | EDGAR |
| 2024-05-17 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2023-11-09 | 4 | Lexeo Therapeutics, Inc. (LXEO) jointly with Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Tammenoms Bakker Juliet | Conversion (C): 1,793,429 · Conversion (C): 319,126 · Purchase (P): 454,545 @ $11 · Conversion (C): 18,999,999 (derivative) · Conversion (C): 2,906,148 (derivative) | EDGAR |
| 2023-08-15 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 3,075 @ $0 · Sale (S): 1,241 @ $138.16 | EDGAR |
| 2023-05-12 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | Vera Therapeutics, Inc. (VERA) | Purchase (P): 1,714,285 @ $7 | EDGAR |
| 2022-11-25 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Sale (S): 2,905 @ $149.18 · Sale (S): 2,069 @ $149.90 · Sale (S): 2,000 @ $152.88 | EDGAR |
| 2022-08-09 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 2,561 @ $0 · Sale (S): 1,089 @ $152.33 | EDGAR |
| 2022-05-31 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 9,925 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4 | Sierra Oncology, Inc. (SRRA) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P. | Other (J): 175,000 @ $0 · Other (J): 1,964,771 @ $0 · Other (J): 5,023 @ $0 · Other (J): 2,152 @ $0 · Other (J): 7,175 @ $0 · Other (J): 588 @ $0 · +2 more | EDGAR |
| 2022-04-21 | 4 | Inozyme Pharma, Inc. (INZY) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet | Purchase (P): 1,355,000 @ $3.69 | EDGAR |
| 2022-04-05 | 4 | Vera Therapeutics, Inc. (VERA) | Purchase (P): 333,333 @ $15 | EDGAR |
| 2022-02-02 | 4 | Sierra Oncology, Inc. (SRRA) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P. | Purchase (P): 175,000 @ $27 | EDGAR |
| 2022-01-27 | 4 | Sierra Oncology, Inc. (SRRA) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet | Option exercise/expiry (X): 487,451 @ $13.20 · Option exercise/expiry (X): 1,477,125 (derivative) @ $13.20 | EDGAR |
| 2021-08-20 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 2,000 @ $137.75 | EDGAR |
| 2021-08-02 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Grant/award (A): 2,246 @ $0 | EDGAR |
| 2021-07-20 | 4 | RAPID MICRO BIOSYSTEMS, INC. (RPID) jointly with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Tammenoms Bakker Juliet | Conversion (C): 3,344,038 @ $0 · Purchase (P): 150,000 @ $20 · Conversion (C): 8,774,007 (derivative) @ $0 · Conversion (C): 5,654,529 (derivative) @ $0 · Conversion (C): 2,291,665 (derivative) @ $0 · Conversion (C): 2,500,000 (derivative) @ $0 · +3 more | EDGAR |
| 2021-06-01 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Vera Therapeutics, Inc. (VERA) | Conversion (C): 2,187,504 · Purchase (P): 909,090 @ $11 · Conversion (C): 2,187,504 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 9,925 (derivative) @ $0 | EDGAR |
| 2021-05-11 | 4 | Talaris Therapeutics, Inc. (TALS) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet | Conversion (C): 2,985,775 · Purchase (P): 235,000 @ $17 · Conversion (C): 1,308,410 (derivative) @ $0 · Conversion (C): 1,271,027 (derivative) @ $0 · Conversion (C): 406,338 (derivative) @ $0 | EDGAR |
| 2021-04-15 | 4 | Eargo, Inc. (EAR) jointly with Longitude Venture Partners IV, L.P., Longitude Capital Partners IV, LLC | Other (J): 1,000,000 @ $0 · Other (J): 5,012 @ $0 | EDGAR |
| 2021-01-05 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 8,149 (derivative) @ $2.22 | EDGAR |
| 2020-11-18 | 4 | 89bio, Inc. (ETNB) jointly with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet | Other (J): 850,000 @ $0 · Other (J): 2,973 @ $0 · Other (J): 2,080 @ $0 · Other (J): 891 @ $0 | EDGAR |
| 2020-11-13 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Sale (S): 3,223 @ $145.81 · Sale (S): 5,083 @ $147.00 · Sale (S): 1,623 @ $147.61 | EDGAR |
| 2020-11-04 | 4 | Jazz Pharmaceuticals plc (JAZZ) | Option exercise (M): 9,929 · Option exercise (M): 9,929 (derivative) | EDGAR |
| 2020-10-22 | 4 | Eargo, Inc. (EAR) jointly with Longitude Venture Partners IV, L.P., Longitude Capital Partners IV, LLC | Conversion (C): 3,685,358 · Purchase (P): 233,333 @ $18 · Conversion (C): 3,685,358 (derivative) @ $0 | EDGAR |
| 2020-10-14 | 4 | Aimmune Therapeutics, Inc. (AIMT) | Code (U): 70,561 @ $34.50 · Code (U): 91,697 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 65,849 (derivative) @ $34.36 · Disposition to issuer (D): 52,421 (derivative) @ $28.21 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · +4 more | EDGAR |
| 2020-10-02 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 8,379 (derivative) @ $2.16 | EDGAR |
| 2020-09-23 | 4 | Aimmune Therapeutics, Inc. (AIMT) | Other (J): 6,113,134 @ $0 · Other (J): 91,697 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1253886 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs